Literature DB >> 9703277

Reversal of vinblastine transport by chlorpromazine in membrane vesicles from multidrug-resistant human CCRF-CEM leukaemia cells.

S K Syed1, R I Christopherson, B D Roufogalis.   

Abstract

The mechanism of action of 2-chlorpromazine (2-chloro-10-(3-dimethylaminopropyl)-phenothiazine) as a reversal agent for P-glycoprotein-mediated multidrug resistance was investigated using inside out-orientated membrane vesicles prepared from vinblastine-resistant human CCRF-CEM leukaemia cells (VBL1000). 2-Chlorpromazine (10 microM) completely inhibited ATP-dependent P-glycoprotein-mediated vinblastine accumulation in the vesicles. Whereas in the absence of added ligands VBL transport was described by a hyperbolic function of vinblastine concentration, in the presence of 2-chlorpromazine vinblastine transport was a sigmoidal function. 2-Chlorpromazine was shown previously [Syed SK, Christopherson RI and Roufogalis BD (1996) Biochem Mol Biol Int 39: 687-696] to be actively transported into vesicles from multidrug-resistant cells. Colchicine (10 microM) and phenoxybenzamine (10 microM) blocked vinblastine transport but had no effect on 2-chlorpromazine transport into vesicles. The results were consistent with a two-state concerted model in which P-glycoprotein exists in two conformational states, P(A) and P(B), where 2-chlorpromazine is transported by the conformer, P(A), and vinblastine by the conformer, P(B). In the presence of 2-chlorpromazine, the conformer P(A) predominates and vinblastine transport is inhibited. Addition of 2-chlorpromazine during the steady state of vinblastine accumulation blocked uptake and resulted in enhanced vinblastine efflux from the vesicles. The findings were similar when vinblastine was added at the steady state of 2-chlorpromazine transport. We propose a minimal kinetic model whereby in these preloaded vesicles the complex VV.P(A).CC is formed, where two internal binding sites of P-glycoprotein (P(A)) are occupied by vinblastine (V) and the two external sites are occupied by 2-chlorpromazine (C). When the two binding sites on both the inside and outside of P-glycoprotein are saturated with ligands vinblastine is effluxed at a very rapid rate, and vice versa when vesicles are preloaded with 2-chlorpromazine and vinblastine is added outside. These unexpected observations and the concerted model developed provide an alternative mechanism of action for reversal agents that sensitize multidrug-resistant cancer cells to anti-cancer drugs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9703277      PMCID: PMC2063016          DOI: 10.1038/bjc.1998.493

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  29 in total

1.  ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells.

Authors:  M Horio; M M Gottesman; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

2.  Discrete mutations introduced in the predicted nucleotide-binding sites of the mdr1 gene abolish its ability to confer multidrug resistance.

Authors:  M Azzaria; E Schurr; P Gros
Journal:  Mol Cell Biol       Date:  1989-12       Impact factor: 4.272

Review 3.  The multidrug transporter, a double-edged sword.

Authors:  M M Gottesman; I Pastan
Journal:  J Biol Chem       Date:  1988-09-05       Impact factor: 5.157

4.  Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance.

Authors:  J M Ford; W C Prozialeck; W N Hait
Journal:  Mol Pharmacol       Date:  1989-01       Impact factor: 4.436

5.  Transport characteristics of [3H]-chlorpromazine across rat small intestinal brush border membrane.

Authors:  H Saitoh; S Kawai; K Iseki; K Miyazaki; T Arita
Journal:  J Pharm Pharmacol       Date:  1989-03       Impact factor: 3.765

6.  Plasma membrane lipid composition of vinblastine sensitive and resistant human leukaemic lymphoblasts.

Authors:  G L May; L C Wright; M Dyne; W B Mackinnon; R M Fox; C E Mountford
Journal:  Int J Cancer       Date:  1988-11-15       Impact factor: 7.396

7.  Effect of cyclosporin A on daunorubicin accumulation in multidrug-resistant P388 leukemia cells measured by real-time flow cytometry.

Authors:  K Nooter; R Oostrum; R Jonker; H van Dekken; W Stokdijk; G van den Engh
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

8.  Reduced drug accumulation in multiply drug-resistant human KB carcinoma cell lines.

Authors:  A Fojo; S Akiyama; M M Gottesman; I Pastan
Journal:  Cancer Res       Date:  1985-07       Impact factor: 12.701

9.  Vinblastine photoaffinity labeling of a high molecular weight surface membrane glycoprotein specific for multidrug-resistant cells.

Authors:  A R Safa; C J Glover; M B Meyers; J L Biedler; R L Felsted
Journal:  J Biol Chem       Date:  1986-05-15       Impact factor: 5.157

10.  Most drugs that reverse multidrug resistance also inhibit photoaffinity labeling of P-glycoprotein by a vinblastine analog.

Authors:  S Akiyama; M M Cornwell; M Kuwano; I Pastan; M M Gottesman
Journal:  Mol Pharmacol       Date:  1988-02       Impact factor: 4.436

View more
  3 in total

1.  Selective modulation of P-glycoprotein-mediated drug resistance.

Authors:  M Bebawy; M B Morris; B D Roufogalis
Journal:  Br J Cancer       Date:  2001-12-14       Impact factor: 7.640

Review 2.  Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL.

Authors:  Lucy Hare; G A Amos Burke; Suzanne D Turner
Journal:  Cancers (Basel)       Date:  2021-11-29       Impact factor: 6.639

3.  Novel Thiazolo[5,4-b]phenothiazine Derivatives: Synthesis, Structural Characterization, and In Vitro Evaluation of Antiproliferative Activity against Human Leukaemia.

Authors:  Balazs Brem; Emese Gal; Luiza Găină; Luminiţa Silaghi-Dumitrescu; Eva Fischer-Fodor; Ciprian Ionuţ Tomuleasa; Adriana Grozav; Valentin Zaharia; Lorena Filip; Castelia Cristea
Journal:  Int J Mol Sci       Date:  2017-06-26       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.